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ABSTRACT Latent membrane protein 1 (LMP1) and LMP2A affect cell growth in both epithelial cells and lymphocytes. In this
study, the effects on cellular gene expression were determined by microarray analysis of transgenic mice expressing LMP1,
LMP2A, or both using the immunoglobulin heavy chain promoter and enhancer. Large differential changes were detected, indi-
cating that LMP1 and LMP2A can both potently affect host gene transcription, inducing distinct transcriptional profiles. Sev-
enty percent of the changes detected in LMP1/2A doubly transgenic lymphocytes were also modulated by LMP1 or LMP2A alone.
These common and unique expression changes indicate that the combined effects of LMP1 and LMP2A may be additive, syner-
gistic, or inhibitory. Using significant pathway analysis, the expression changes detected in LMP1, LMP2A, and LMP1/2A trans-
genic B lymphocytes were predicted to commonly target cancer and inflammatory pathways. Additionally, using the correlation
coefficient to calculate the regulation of known c-Rel and Stat3 transcriptional targets, both were found to be enhanced in LMP1
lymphocytes and lymphomas, and a selection of Stat3 targets was further evaluated and confirmed using quantitative reverse
transcription-PCR (RT-PCR). Analyses of the effects on cell growth and viability revealed that LMP2A transgenic lymphocytes
had the greatest enhanced viability in vitro; however, doubly transgenic lymphocytes (LMP1/2A) did not have enhanced survival
in culture and these mice were similar to negative littermates. These findings indicate that the combined expression of LMP1 and
LMP2A has potentially different biological outcomes than when the two proteins are expressed individually.
IMPORTANCE The Epstein-Barr virus proteins latent membrane protein 1 (LMP1) and LMP2A have potent effects on cell growth.
In transgenic mice that express these proteins in B lymphocytes, the cell growth and survival properties are also affected. LMP1
transgenic mice have increased development of lymphoma, and the LMP1 lymphocytes have increased viability in culture.
LMP2A transgenic lymphocytes have altered B cell development and enhanced survival. In this study, analysis of the cellular
gene expression changes in transgenic LMP1 and LMP2A lymphocytes and LMP1 lymphomas revealed that both transgenes indi-
vidually and in combination affected pathways important for the development of cancer and inflammation. Importantly, the
combined expression of the two proteins had unique effects on cellular expression and cell viability. This is the first study to look
at the combined effects of LMP1 and LMP2A on global changes in host gene expression.
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Epstein-Barr virus (EBV) is a human gammaherpesvirus that iscausally linked to a variety of B cell lymphomas, including
Burkitt lymphoma (BL), Hodgkin lymphoma (HL), and post-
transplant and AIDS-associated lymphomas, and the epithelial
cell cancers nasopharyngeal carcinoma and gastric carcinoma.
The viral proteins latent membrane protein 1 (LMP1) and LMP2A
have potent effects on cell growth, including oncogenic and pro-
survival properties. LMP1 is considered the principal viral onco-
protein as it can transform rodent fibroblasts to tumorigenicity
in nude mice and is required for EBV B cell immortalization.
Functionally, LMP1 mimics a constitutive member of the tumor
necrosis factor receptor (TNFR) family as it interacts with
TNFR-associated molecules, including TRAFs, TRADD, and
RIP (1–5). LMP1 activates multiple signaling pathways, including
NF-B, Stat3, and mitogen-activated protein kinase (MAPK).
LMP2A also affects cell growth, and in B lymphocytes, it alters
B cell receptor signaling and can promote the survival of
immunoglobulin-negative B cells in transgenic mice (6–11). In
epithelial cells, LMP2A inhibits differentiation and promotes cell
migration (12–16). The effects of LMP2A are mediated through its
direct recruitment of Src and Syk family tyrosine kinases and ac-
tivation of phosphatidylinositol 3-kinase (PI3-kinase) and Akt
(16–18).
Both LMP1 and LMP2A transgenic mouse models with expres-
sion regulated under the control of the immunoglobulin heavy
chain promoter and enhancer have been generated and character-
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ized (8, 19, 20). Expression of LMP1 in B lymphocytes of trans-
genic mice results in increased development of lymphoma in ap-
proximately 50% of mice over 12 months old, and a recent study
indicates that suppression of the immune response increases this
incidence (19–21). The lymphomas in both studies develop in the
CD5 (B-1a) subset of lymphocytes, a self-renewing population
of B cells predisposed to clonal expansion with age and frequently
detected in the peritoneal and pleural cavity (20). The LMP1
transgenic lymphocytes have enhanced survival in vitro, and this
effect requires activation of NF-B and Stat3 (20). The LMP1
lymphomas have rearranged immunoglobulin genes and have
activated Akt, Jun N-terminal protein kinase (JNK), p38, and NF-
B, with specific activation of the NF-B family member c-Rel
(19, 20, 22). In transgenic mice that express high levels of
LMP2A in B cells, a survival signal is induced that enables
immunoglobulin-negative B cells normally destined to die from
apoptosis to bypass developmental checkpoints and survive in the
peripheral blood (6, 8). These transgenic systems provide a unique
opportunity to investigate the in vivo effects of LMP1 and LMP2A
on cellular gene expression and to identify specific pathways that
may contribute to lymphoma development and survival of pri-
mary B cells in culture.
In this study, the effects of LMP1 on cellular gene expression in
the transgenic B cells and transgenic lymphomas were determined
using expression microarray analysis. Additionally, the effect of
LMP2A on B cell gene expression was assessed alone and in com-
bination with LMP1. Interestingly, pathway analysis identified
significant effects on cancer and inflammation for LMP1, LMP2A,
and LMP1/2A doubly transgenic lymphocytes. The data indicate
that LMP1 and LMP2A can potently and distinctly affect host gene
transcription and that their combined expression is not necessar-
ily additive but can have unique effects on gene expression with
potentially different biological outcomes.
RESULTS
Gene expression profiling of transgenic B lymphocytes and lym-
phoma cells. To obtain sufficient material for analysis and to ob-
tain pure populations of malignant splenic lymphoma cells, pri-
mary lymphomas were inoculated and passaged in SCID mice.
The LMP1 lymphomas could be consistently established as xeno-
grafts; however, only one spontaneous lymphoma that developed
in a negative littermate was also successfully passaged. Interest-
ingly, the doubly transgenic mice did not have lymphoma inci-
dence enhanced above that of LMP1 transgenic mice. For mi-
croarray analysis, three distinct LMP1 transgenic lymphomas, one
negative lymphoma, and splenic CD19 B lymphocytes from neg-
ative littermates and LMP1, LMP2A, and LMP1/2A transgenic
mice were analyzed as test samples. The three separate LMP1 lym-
phomas were chosen to represent low, medium, and high levels of
LMP1 expression and have been previously characterized as hav-
ing enhanced growth and survival effects relative to the wild-type
lymphoma (20). For lymphocytes, transgene expression was ver-
ified using reverse transcription-PCR (RT-PCR) and two to five
biological replicates were pooled to obtain sufficient RNA for
analyses and to reduce variation between single samples. Test
samples were analyzed by 2-color hybridization using a pool of
splenic CD19 B lymphocytes from multiple control BALB/c
mice as the reference sample. To enable direct comparison be-
tween test samples, the same reference was used between different
microarray hybridizations. The three LMP1-positive and one
spontaneous lymphoma sample were hybridized to one 4x44K
microarray chip (Agilent whole-mouse genome microarray). One
set of pooled LMP1, LMP2A, LMP1/2A, and negative littermate
lymphocyte samples was hybridized in duplicate to two microar-
ray chips which revealed a high degree of technical reproducibil-
ity. The microarray platform represents 41,000 genes and tran-
scripts, mapping to 20,937 genes recognized by ingenuity pathway
analysis (IPA). The data set was assessed using hierarchical clus-
tering and analyzed for genes that are 2-fold changed compared
to the CD19 splenic B cells of negative littermates.
Using hierarchical clustering to display the differences in
normalized expression values, the lymphoma cells clustered
separately from the normal lymphocytes (Fig. 1). The LMP1 lym-
phoma cells were more similar to the negative wild-type lym-
phoma than to the normal LMP1 transgenic lymphocytes. Previ-
FIG 1 Heat map of all detected probes for transgenic lymphocytes and lym-
phoma cells. Hierarchical clustering and expression relationships were ana-
lyzed for enriched GO terms using GeneSpring GX. The bracket tree indicates
similarity between transgenic samples. Normalized expression value relative to
the reference sample (control BALB/c mice) is indicated in the legend: upregu-
lation (red), downregulation (blue), and no change (yellow).
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ous analyses of the LMP1 and wild-type lymphomas have also
shown that the lymphomas are similar with regard to extended
survival in vitro and for the requirement for the same activated
signaling pathways (20). The LMP2A transgenic lymphocytes
clustered separately from the other genotypes (negative, LMP1,
and LMP1/2A), indicating the most distinct gene expression pro-
file (Fig. 1). Gene expression profiles were also clustered based on
expression trends relative to the reference sample, generating
three recognizable categories: no change or slightly downregu-
lated, no change or slightly upregulated, and large variation in
expression in any direction (Fig. 1). The genes with the greatest
changes in expression levels were enriched for gene ontology (GO)
terms in intracellular and cell surface components involved in
processes such as cell cycle, cell death, immune/stress responses,
DNA replication, and protein metabolism. This suggests that
transgene expression is most likely to affect cell growth, survival,
and immune response processes.
LMP2A lymphocytes had the greatest number of genes
changed at least 2-fold (3,808 genes) relative to the negative litter-
mates, which was nearly twice as many changes as were detected
for LMP1 (1,660 genes) or LMP1/2A (1,656 genes) (Fig. 2A). Ap-
proximately 70% (1,166/1,656) of the entities changed in the dou-
bly transgenic LMP1/2A lymphocytes were commonly changed by
LMP1 or LMP2A expression alone (Fig. 2A). The remaining 30%
(490/1,656) may represent unique effects of LMP1 and LMP2A
coexpression.
Expression in the LMP1 lymphomas was compared to the
wild-type lymphoma by identifying genes consistently changed
2-fold in the same direction (up/down) in every LMP1 lym-
phoma (high/medium/low). This comparison identified 1,334
genes changed greater than 2-fold in the same direction in all three
LMP1 lymphomas. Comparison with the 1,660 genes changed in
the LMP1 transgenic lymphocytes relative to negative littermates
indicated that approximately 1/10 (184/1,334) of the genes
changed 2-fold in LMP1 lymphomas were also commonly
changed in LMP1 lymphocytes (Fig. 2B). The common genes were
further filtered to consider the direction of change (up/down) and
to retain only genes that were changed in the same direction in
every LMP1 lymphoma sample and in the LMP1 lymphocytes.
Out of 184 common genes (Fig. 2B), this retained 93 genes
changed in the same direction (60 genes up, 33 genes down).
These genes are displayed by GO terms in their respective func-
tional categories (see Table S1 in the supplemental material).
These findings indicate that LMP1 has distinct effects in normal
versus malignant cells.
Identification of significantly changed pathways and valida-
tion of targets by quantitative RT-PCR (qRT-PCR). To predict
pathways that are significantly represented in the gene list gener-
ated from 2-fold change comparisons, “significant pathway anal-
ysis” from GeneSpring GX was performed. The pathways chosen
for comparison were derived from the BioPAX database and in-
clude the Cancer Cell Map and Integrating Network Objects with
Hierarchies databases. These represent curated signaling path-
ways involved in processes such as cell growth, death, attachment,
immune recognition, and cytokine signaling. Pathways were con-
sidered significant with a P value cutoff of 0.05, taking into ac-
count the representation of the pathway entities on the array plat-
form used.
Consistent with the greater number of genes that were affected
in the LMP2A lymphocytes, many more significant pathways
were identified for LMP2A lymphocytes than for the LMP1 or
LMP1/2A genotypes (Table 1). These pathways included Notch,
Wnt, transforming growth factor  (TGF-), and integrin signal-
ing, which have been experimentally linked to the function of
LMP2A in B lymphocytes and epithelial cells, lending support to
the validity of the predicted pathways (17, 23–26). Interestingly,
the c-Kit receptor signaling pathway, a receptor tyrosine kinase
and proto-oncogene involved in a variety of hematological malig-
nancies and solid cancers, was identified as a significant pathway
in LMP2A lymphocytes with 23 genes affected from the 63 c-Kit
involved genes represented on the array. The LMP2A transgenic
mice do not have increased lymphoma incidence, and so the ef-
fects on the c-Kit pathway may reflect the effects of LMP2A on cell
survival or B cell signaling.
The expression analyses identified two significant pathways for
LMP1 lymphocytes which were enriched for genes in JAK/STAT
and tumor necrosis factor alpha (TNF-)/NF-B signaling path-
ways. In the JAK/STAT pathway, the negative regulators Sirpa and
Ptpn6 were downregulated. Sirpa encodes a receptor-type trans-
membrane glycoprotein that recruits protein tyrosine phospha-
tases such as Ptpn6 to dephosphorylate activated protein tyrosine
kinases such as JAK1 and JAK2. The loss of Sirpa and Ptpn6 could
contribute to the previously described independence from
interleukin-4 (IL-4) stimulation in LMP1 transgenic lymphocytes
and lymphoma cells and the constitutive activation of Stat3 that is
required for their enhanced survival in culture (20). These path-
ways were not identified in the expression arrays of the doubly
transgenic LMP1/2A lymphocytes. However, multiple pathways
significantly affected in the doubly transgenic lymphocytes were
in common with the LMP2A lymphocytes, including TGF-,
Notch, and Wnt signaling. Pathways uniquely represented in
LMP1/2A lymphocytes include IL-1, toll-like receptor, ID, and
Hedgehog signaling, which could reflect the combined effects of
LMP1 and LMP2A (Table 1).
To identify pathways modified by LMP1 in lymphoma cells,
significant pathway analysis was performed on differential genes
consistently changed 2-fold in the same direction in every com-
parison of LMP1 lymphoma (low/medium/high expression) to
wild-type lymphoma. The c-Kit receptor pathway was identified
as significant (P  0.05); interestingly, it was also identified as
significant in LMP2A lymphocytes (Table 1). This may indicate
FIG 2 Venn diagrams of differentially regulated genes from transgenic lym-
phocytes and lymphoma cells. Shown are differential genes from transgenic
lymphocytes (LMP1, LMP2A, and LMP1/2A) (a) and LMP1 transgenic lym-
phocytes and lymphoma cells (b). Differential lists represent 2-fold changes
relative to the negative lymphocyte or lymphoma.
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that LMP2A can enhance pathways commonly induced by LMP1.
Previous characterization of the biological properties and acti-
vated signaling pathways has revealed that the LMP1 transgenic
lymphomas and the spontaneous lymphoma are quite similar (20,
22). This similarity is reflected in the few changes that distinguish
the LMP1 lymphomas. The JAK/STAT pathway which was iden-
tified for LMP1 lymphocytes was not significantly changed by
LMP1 in lymphoma cells. This likely reflects the constitutive acti-
vation of Stat3 in both the LMP1 transgenic and spontaneous
lymphomas, indicating that alterations in the JAK/STAT pathway
are commonly affected in the lymphoma cell state (20). However,
the activation of this pathway in LMP1 lymphocytes may be one of
the contributing factors to the enhanced development of lym-
phoma from this precancerous population.
In order to validate the changes detected by microarray, 13
targets identified from the c-Kit and Stat3 pathways were chosen
for further analysis by qRT-PCR (Table 2). These 13 targets
ranged from small to large changes (1.2- to 28-fold), enabling an
assessment of reproducibility over a wide range. Two indepen-
dently passaged biological replicas of a wild-type and a high-
LMP1-expression lymphoma were analyzed in triplicate reac-
tions. Values were normalized to the housekeeping gene 2-
microglobulin, whose expression did not change across samples as
measured by the coefficient of variation from the microarray data.
To facilitate direct comparison, the first replica utilized the same
preparation of RNA used for microarray hybridizations. In this
first replica, 12/13 targets were confirmed to change in the same
direction by qRT-PCR, of which 10 were further confirmed in the
biological replica (Table 2). Within the confirmed targets, the
overall degree of change was also reproducible, with the largest
TABLE 1 Significant pathway analysis on genes changed 2-fold in transgenic lymphocytes and lymphomasc
Significant pathways







From pathway matched with
gene list (2-fold change)
For LMP1 lymphocytes
Negative regulation of (phosphorylation
of cytokine receptor) in JAK STAT pathway
5 3 2 0.015784
TNF-/NF-B 220 193 21 0.051242
For LMP2A lymphocytes
EGF-R1 180 174 66 E04
Kit receptor 71 63 23 2.35E04
TNF-/NF-B 220 193 53 3.40E04
TGF--R 197 131 39 3.52E04
Canonical Wnt signaling pathway 74 17 9 7.96E04
Mammalian Wnt signaling pathway 70 17 9 7.96E04
Signaling with Wnt (canonical) 45 11 7 8.36E04
Signaling with Wnt (mammal) 44 11 7 8.36E04
Androgen receptor 101 93 29 8.50E04
Xenopus axis formation Wnt signaling pathway 58 15 7 0.007772
Stabilization and accumulation of
cytoplasmic -catenin (canonical)
18 6 4 0.010281
Stabilization and accumulation of
cytoplasmic -catenin (mammal)
17 6 4 0.010281
-Catenin degradation signaling (canonical) 10 4 3 0.014187
-Catenin degradation signaling (mammal) 10 4 3 0.014187
Signaling without Wnt (canonical) 15 4 3 0.014187
Signaling without Wnt (mammal) 15 4 3 0.014187
Notch 94 69 19 0.024539
JNK cascade 9 2 2 0.025317
64 integrin 59 54 15 0.039648
VEGF signaling pathway 50 12 5 0.04288
TGF- signaling pathway (through TAK1) 33 12 5 0.043328
For LMP1/2A lymphocytes
TGF--R 197 131 18 0.009599
Notch 94 69 10 0.033524
IL-1 signaling (through JNK cascade)
(canonical)
48 6 2 0.058911
Toll-like receptor signaling pathway
(through JNK cascade) (canonical)
45 6 2 0.058911
ID 30 30 5 0.071556
Hedgehog 25 22 4 0.07939
Xenopus axis formation
Wnt signaling pathway
58 15 3 0.092978
For LMP1 lymphomas
Kit receptor 71 63 8 0.038117
a BioPAX Cancer Cell Map and Integrating Network Objects with Hierarchies databases were analyzed for enriched pathways in GeneSpring GX.
b Statistically significant (P  0.05), calculated in GeneSpring GX.
c Abbreviations: EGF, epidermal growth factor; VEGF, vascular endothelial growth factor.
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changes detected for Epor, Grb10, Tec, and Yes1. Despite inherent
differences in the two methodologies and in normalization meth-
ods, qRT-PCR indicated a high correlation with the microarray
data. Overall, these correlative qRT-PCR results confirm the mi-
croarray data and indicate that the targets identified by microarray
are reproducible.
Comparison analysis of biological functions and canonical
signaling pathways in transgenic lymphocytes and lymphoma
cells. Biological functions and signaling pathways that were po-
tentially altered by transgene expression were also identified using
IPA. Biological functions with a P value of 0.05 by the Fisher
exact test were considered significant and displayed as “diseases
and disorders” to help categorize gene changes by disease associ-
ations (Table 3). In the lymphocyte comparison, the common
biological functions identified for all transgenic lymphocytes were
cancer and inflammatory response. Interestingly, both LMP1 and
LMP2A transgenic mice have been shown to hyperactivate B cells,
leading to enhanced antibody production and autoimmunity (21,
27–29). IPA can also associate gene expression changes to predict
an increasing (promoting) or decreasing (suppression) effect on a
biological function by using curated information from published
literature. Using this predictive method, most of the changes in-
creased the functions of cancer and inflammatory response path-
ways, indicating that LMP1 and LMP2A can independently acti-
vate cancer and inflammatory mechanisms (Table 3). For
example, AICDA has no predicted function for cancer but is pre-
dicted to increase inflammatory responses. AICDA-deficient mice
develop enlarged germinal centers (GCs) with spontaneously hy-
peractivated IgM nonswitched B cells (30). The decrease in
AICDA expression in LMP1/2A mice (4.154-fold) would thus
predict an increase in inflammatory responses by activating B cells
(Table 3). In contrast, there were more decreased predictions for
metabolic disorders linked to LMP1/2A lymphocyte function,
suggesting that LMP1 and LMP2A alter gene expression signa-
tures that oppose metabolic defects and may thus function to
more efficiently utilize metabolic pathways.
In the lymphoma comparison, LMP1 lymphomas also affected
inflammatory response, similarly to LMP1 lymphocytes, although
distinct genes belonging to inflammatory response functions were
affected (Table 3). Interestingly, LMP1 lymphomas were also dis-
tinguished by changes in infectious diseases, including reactiva-
tion of EBV. Multiple genes were affected in activation of inflam-
matory response, with increases in CD40 and ZEB, which
negatively regulate the expression of the viral BZLF1 lytic-switch
gene (31–33). The LMP1- and/or LMP2A-differentially regulated
genes were placed on the “molecular mechanisms of cancer”
pathway map and highlighted for genes associated with lym-
phomagenesis using IPA. The changes detected for LMP1/2A
lymphocytes (see Fig. S1 in the supplemental material) differed
from the changes detected from individually expressed transgenes
(LMP2A, see Fig. S2; LMP1, see Fig. S3), indicating that the trans-
genes have unique effects on cancer signaling pathways. This anal-
ysis highlights the differences in the effects on key pathways with
LMP1/2A coexpression and single gene expression.
Identifying c-Rel transcriptional targets from the lymphoma
gene list. It is known that activation of the canonical NF-B path-
way is required for survival of EBV-transformed lymphocytes and
the survival of LMP1 transgenic and wild-type lymphoma cells
(20, 34–36). Additionally, the NF-B member c-Rel has been
shown to be specifically activated in LMP1 transgenic and wild-
type lymphomas, suggesting that c-Rel is the required NF-B
member for maintaining survival (22). The 175 experimentally
determined c-Rel transcriptional targets identified from the Inge-
nuity Knowledge Base were compared with 2-fold changes in
the lymphoma samples. Targets both commonly affected and
uniquely affected in the wild-type or LMP1-expressing lympho-
mas were identified (see Table S2 in the supplemental material).
Interestingly, several of the genes previously identified to be af-
fected by LMP1 in cell lines are confirmed c-Rel targets, including
ICAM1, MMP9, and IL-6.
The correlation coefficient (r) was calculated for the expression
of all queried c-Rel targets in lymphoma and lymphocyte cells
expressing LMP1 relative to their corresponding expression in the
negative genotype (Fig. 3). An r value of 1 indicates a perfect
linear relationship, indicating no difference in the expression of
c-Rel targets, whereas a value of 1 indicates no linear relation-
ship and a definitive change in expression. Comparison between
the same cell states, e.g., between lymphocytes (LMP1 versus neg-
ative) or between lymphoma cells (LMP1-LL high/medium/low
versus WT-LL), indicated the least change or most similar expres-
sion profiles as indicated by the highest r values (r range, 0.73 to
0.78). In contrast, comparison between the lymphoma cells






(LMP1-LL high relative to WT-LL)
qRT-PCR, 1st replica
(LMP1-LL high relative to WT-LL)
qRT-PCR, 2nd replica
(LMP1-LL high relative to WT-LL)
Kitl c-Kit 10.13 1.18 1.44
Kit c-Kit 3.48 2.08a 1.68a
Csf2rb c-Kit 2.52 5.34a 2.02a
Tec c-Kit 3.25 5.84a 4.24a
Yes1 c-Kit 3.93 3.67a 3.55a
Epor c-Kit 28.00 12.67a 23.48a
Grb10 c-Kit 6.57 5.79a 2.31a
Cblb c-Kit 2.49 2.98a 1.36a
Birc5 Stat3 1.55 1.28a 3.59
Ccne1 Stat3 1.26 1.25a 3.21
Cdkn1a Stat3 1.47 1.64a 1.65a
Adm Stat3 1.25 2.7a 2.72a
Myb Stat3 1.76 1.54a 1.4a
a Targets confirmed to change in the same direction as in microarray analysis.
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Predicted outcome of function
(based on expression direction)




















Cancer A_52_P348214 BCL2L11 3.131 A_52_P432647 ICOSLG 3.227 A_51_P229664 CD27 5.955
A_52_P278549 MYC 2.993 A_52_P11174 HIP1 3.715 A_52_P339495 PDIA6 3.2491
A_52_P309376 JAK2 2.549 A_52_P116298 MYBL1 4.215 A_51_P137111 CHEK2 2.925
A_52_P638895 VEGFA 2.34 A_51_P208240 TNFSF14 2.78
A_51_P365757 FIP1L1 2.005 A_52_P244956 AICDA 4.154
A_51_P400453 PTEN 2.192
Inflammatory response— A_51_P430766 IL-10 13.836 A_52_P162967 CD28 5.484 A_51_P270807 TNFRSF17 4.285
activation A_51_P196925 CX3CL1 10.707 A_52_P15461 IL-15 5.138 A_52_P507214 MMP9 2.836
A_51_P318104 APP 6.99 A_51_P181286 CD69 4.391 A_52_P427024 LDLR 2.533
A_52_P165705 CD1D 4.606 A_51_P260683 RGS1 4.238 A_52_P490788 CR2 3.186
A_51_P418295 CD80 4.48 A_52_P98698 Klra4 2.96
A_51_P387591 NFKBIZ 3.834 A_51_P338746 PRDM1 2.933
A_51_P432641 CXCL10 2.456 A_52_P161495 BCL6 2.963








Diabetes mellitus A_51_P418295 CD80 4.48
A_51_P285736 PDCD1 4.065
Light chain-associated A_51_P229664 CD27 5.955





Cancer A_52_P116298 MYBL1 3.413 A_51_P137111 CHEK2 3.482
A_52_P309376 JAK2 2.301 A_52_P339495 PDIA6 2.469
A_51_P172266 IL9R 2.187
A_51_P229664 CD27 2.004
Inflammatory response— A_52_P165705 CD1D 3.049 A_52_P15461 IL-15 2.821
activation A_52_P484194 IL1RL1 2.025
LMP2A lymphocyte
Cancer A_52_P348214 BCL2L11 4.4 A_51_P400453 PTEN 3.278 A_51_P229664 CD27 5.161
A_51_P102096 MYC 4.297 A_52_P781398 TP53 2.736 A_51_P482508 MSMO1 2.172
A_52_P309376 JAK2 3.181 A_52_P469842 MDM2 2.396 A_52_P70810 PDIA6 2.063
A_52_P638895 VEGFA 2.31 A_52_P116298 MYBL1 2.919 A_51_P137111 CHEK2 2.504
A_51_P483059 DICER1 2.077 A_52_P244956 AICDA 2.614
Inflammatory response— A_51_P430766 IL-10 15.521 A_52_P162967 CD28 3.855 A_51_P171999 APOE 2.247
activation A_52_P244005 CD80 4.247 A_51_P181286 CD69 2.778 A_52_P222026 CHRNB2 2.132
A_52_P420792 TXNIP 2.507 A_51_P252103 SLA2 2.544 A_52_P427024 LDLR 2.871
A_52_P566867 BCL10 2.243 A_51_P201480 Stat3 2.079 A_51_P142320 PIK3CD 3.008
A_51_P257934 TNFSF13B 2.065 A_51_P146320 SEMA4D 2.054 A_52_P426049 LAT2 3.033
A_52_P73385 FAS 2.019 A_52_P667098 TPT1 2.115
A_52_P451929 Lilrb3 2.023 A_51_P154780 VAV1 2.395
A_52_P466268 CD22 2.192 A_52_P179785 RIPK2 4.238




Inflammatory response— A_51_P424338 NQO1 6.4 A_51_P255853 TAL1 11.222 A_52_P661044 CCR3 3.267
activation A_51_P475995 THRA 5.325 A_51_P339793 IL1RL1 6.861 A_52_P222026 CHRNB2 2.422
A_51_P420229 CCR7 3.716 A_51_P489192 POSTN 6.693 A_52_P472888 MALT1 4.164
A_51_P366138 MERTK 2.342 A_51_P428708 C4B 3.777 A_51_P105887 LAX1 5.184
A_51_P210956 VCAM1 2.253 A_52_P409601 CD40 2.475
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(LMP1-LL high/medium/low, WT-LL)
and the negative lymphocytes revealed
the greatest differences in expression val-
ues (r range, 0.2 to 0.39). Additionally, the
number of upregulated genes that satis-
fied the 2-fold cutoff was used to pre-
dict whether c-Rel targets were affected by
up (2) or down (2) regulation.
There were more genes changed by up-
regulation in LMP1 lymphocytes and in
all lymphoma cells (Fig. 3). Overall, the
pathway overlay and correlation coeffi-
cient analysis support the experimental
observation that c-Rel is activated in both
LMP1 transgenic and wild-type lym-
phoma cells and that this activation leads
to transcriptional upregulation of c-Rel
targets (22).
Identifying Stat3 transcriptional tar-
gets from LMP1 lymphocytes and the
lymphoma gene list. Stat3 is constitu-
tively activated in the nucleus of LMP1
lymphocytes and lymphoma cells, and in-
hibition of Stat3 using the drug cucurbit-
acin I decreased viability in primary B cell
cultures (20). To identify important Stat3
transcriptional targets induced by LMP1
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A_52_P247424 SH2B3 2.938 A_51_P316042 CARD11 2.483
A_52_P237087 CD180 3.443 A_52_P566867 BCL10 2.754
A_51_P349341 NPC1 3.494 A_52_P502577 S1PR3 2.844
A_52_P466268 CD22 4.135 A_52_P77106 FASLG 3.063
A_52_P68893 IFNG 4.535 A_51_P495242 LAT 3.471
A_51_P261517 TYROBP 5.066 A_51_P345121 CD8A 3.793








Inflammatory disease—colitis A_52_P409601 CD40 2.475 A_51_P358765 SPP1 99.857
Infectious disease
Reactivation of virus A_52_P409601 CD40 2.475 A_52_P32733 NF-B1 7.723
A_52_P1083741 ZEB1 2.828
Quantity of virus A_51_P261517 TYROBP 5.066
A_51_P284608 CD74 5.67
Infection by bacteria A_51_P351015 LTA 18.439 A_52_P68893 IFNG 4.535 A_52_P32733 NF-B1 7.723
a Pathways grouped by “diseases and disorders” were analyzed for enriched pathways by using ingenuity pathway analysis. Statistically significant (P  0.05, Fisher’s exact test).
b Fold changes for LMP1 lymphomas are averaged values.
FIG 3 Correlation coefficient analysis comparing the regulations of c-Rel transcriptional targets from
CD19 splenic LMP1-positive and -negative lymphocytes and lymphoma cells. The Pearson correla-
tion coefficient r of normalized expression values is displayed for c-Rel transcriptional targets defined by
IPA. A linear regression is shown to indicate a 2-fold change cutoff. Each point indicates a probe
detected on the microarray, and the number of corresponding genes that are up-/downregulated is
indicated in parentheses.
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overlay and correlation coefficient calculation were performed.
To more specifically elucidate cancer-relevant transcriptional tar-
gets, Stat3 direct targets as defined by the Ingenuity Knowledge
Base were filtered to retain genes that have been experimentally
shown to be transcriptionally regulated by Stat3 and linked to
cancer pathways, resulting in a total of 182 potential targets. The
majority of Stat3-responsive genes induced in lymphoma cells
were affected in both wild-type and LMP1 lymphomas; however,
there was also a subset of unique targets upregulated by each ge-
notype (see Table S3 in the supplemental material). The large
number of Stat3-responsive genes induced in lymphoma cells
compared to LMP1 lymphocytes (66 versus 8 genes [see Table S3])
indicates that Stat3 transcriptional activation is increased in lym-
phoma cells. The correlation coefficients support this prediction
that Stat3 targets are most dramatically affected in lymphoma cells
as assessed by the lowest correlation coefficients (r  0.18 to 0.39)
compared to negative lymphocytes (Fig. 4). In the same compar-
isons to negative lymphocytes, more genes were upregulated than
downregulated in all lymphoma cells (wild type and LMP1) as well
as in LMP1 lymphocytes, indicating an overall induction of Stat3-
responsive genes. These observations suggest that the elevated
phosphorylation of Stat3 in lymphoma cells and LMP1 lympho-
cytes results in the transcriptional activation of Stat3 and the in-
creased expression of Stat3 targets (20).
Cell survival analysis of transgenic B lymphocytes. It has
been previously shown that LMP1 can partially substitute for
CD40 signaling and that the LMP1 transgenic lymphocytes have
enhanced B cell survival in culture which is increased by IL-4
treatment while IL-4 alone does not affect the viability of control
lymphocytes or LMP2A lymphocytes (20, 37). To compare the
viabilities of the transgenic lymphocytes
in vitro and to determine the response to
IL-4 treatment, LMP1, LMP2A, and dou-
bly transgenic LMP1/2A mice were ana-
lyzed in splenocyte cultures and com-
pared to negative littermates. Live B cell
populations were analyzed by flow cy-
tometry and enumerated by gating for
CD19 B cells and for annexin V-/pro-
pidium iodide-negative live cells. In
freshly isolated splenocytes, the majority
(80%) of negative-littermate B cells were
alive (Fig. 5a). This was significantly
higher than the live cell populations in
any of the transgenic lymphocyte popula-
tions (LMP1, LMP2A, and LMP1/2A, P 
0.05), indicating that in vivo transgenic
lymphocytes are susceptible to cell death.
However, after 1 day in culture, only 25%
of the negative-littermate B cells survived
and IL-4 supplementation did not in-
crease viability (Fig. 5b and c). LMP2A
transgenic B cells had the highest level of
survival, with approximately 60% viabil-
ity, which was significantly higher than
that of the negative-littermate cells and
other transgenic lymphocytes (LMP1 and
LMP1/2A) (P  0.05) (Fig. 5b). The via-
bility was not enhanced by IL-4 treat-
ment, confirming similar studies using
LMP2 transgenic mice that expressed lower levels of LMP2A (Tg6
lineage) than did the TgE lineage used in this study (Fig. 5c) (6,
37). LMP1 transgenic B cells had increased survival compared to
negative littermates (Fig. 5b), and this effect was slightly enhanced
by IL-4 treatment (Fig. 5c, P  0.05). Interestingly, doubly trans-
genic lymphocytes (LMP1/2A) did not have enhanced survival in
culture and were not significantly different from cells from nega-
tive littermates (Fig. 5b). Treatment with IL-4 did not affect their
viability (Fig. 5c). This survival analysis indicates that coexpres-
sion of LMP1 and LMP2A is not necessarily synergistic and that
LMP2A expression may negate the effects of LMP1.
Comparison of microarray gene expression data to pub-
lished data sets. The data in this study were compared to other
published data sets for expression of LMP1 and/or LMP2A in B
lymphocytes. In the gene expression profiling from the original
LMP2A transgenic line, the majority (96%, 8,583/8,908 IPA-
mapped genes) of the array elements are also represented on the
Agilent array used in the current study. Given the high degree of
overlap in coverage, the differential gene list for CD19 splenic
LMP2A lymphocytes in this study was directly compared to the
differential gene list from the same population of lymphocytes
isolated from the original transgenic line. Comparing the func-
tional categories previously selected for likelihood of EBV disease
association (25), approximately 29% (52/184 genes) overlapped
in the same direction with the gene list from the current analysis
and inflammation/immunity again appeared as the top overlap-
ping function (Fig. 6a). Interestingly, the c-Kit oncogene was also
identified as a differentially expressed gene grouped in the signal-
ing category (see Table S4 in the supplemental material). Other
top-ranking functions, including cell cycle/apoptosis, DNA/RNA
FIG 4 Correlation coefficient analysis comparing the regulation of Stat3 transcriptional cancer targets
from CD19 splenic LMP1-positive and -negative lymphocytes and lymphoma cells. The Pearson
correlation coefficient r of normalized expression values is displayed for Stat3 transcriptional cancer
targets defined by IPA. A linear regression is shown to indicate a 2-fold change cutoff. Each point
indicates a probe detected on the microarray, and the number of corresponding genes that are up-/
downregulated is indicated in parentheses.
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metabolism, signaling, transcription factors, and tumor associa-
tion, also had genes that overlapped with the differential gene list
from the current study. The remaining genes that did not overlap
may partially be explained by a difference in mouse strains. The
original transgenic strain is on a full C57BL/6 background while
mice in the current study are the F1 generation of a C57BL/6 and
BALB/c cross. Despite these differences, it is striking that genes in
inflammatory and tumor-associated pathways are consistently the
most affected.
To evaluate how the transgenic lymphocytes from this study
compare to the changes in human cell lines, the differential gene
list for LMP1 transgenic lymphocytes was compared to a pub-
lished data set on human CD10 GC B cells transfected with
LMP1 and the differential gene list expressed in HL cell lines (38).
The 1,657 genes (562 up, 1,095 down) identified as differentially
expressed in LMP1-transfected GC cells were grouped into func-
tional categories according to GO ontology by IPA. The top-
ranking functional categories (satisfying a P value of 0.05) were
compared to the genes that fall under the same functional catego-
ries in the LMP1 transgenic lymphocyte data set from the current
study, taking into account the directionality of change (Fig. 6b; see
also Table S5 in the supplemental material). The amount of over-
lap was low, with approximately 5% (107/2,209) of the genes in
the tested top-ranking categories also identified in the data set
from LMP1 transgenic lymphocytes (Fig. 6b). However, the cate-
gories with the most overlap were genes associated with cell death,
cancer, and cell cycle functions. Despite a low level of overlap,
these genes may be critically relevant to EBV-associated disease.
Interestingly, more than half (57%, 61/107) of the LMP1 overlap-
ping genes were also previously defined to be differentially ex-
pressed in HL cell lines. To test whether these were significantly
enriched for HL signature genes, a 2 calculation was applied. The
expected overlap was calculated from the published data set,
where 45.7% (881/1,926) of the genes differentially regulated by
LMP1 were also differentially regulated in HL cell lines (38). The
observed overlap of 57% was calculated to be significantly en-
riched for HL defined genes with a P value of 0.02. However, there
was no enrichment if the same analysis was applied to all overlap-
ping LMP1 genes without first selecting for significant functional
categories (observed overlap with all LMP1- and HL-specific
genes was 32%, 24/76). This indicates that the effects of LMP1 in
the transgenic mice are in the same functional categories identi-
fied in HL cells and affect a significant number of the same genes.
The microarray data were also compared with LMP1-
dependent gene signatures in EBV-infected BL cells and lympho-
blastoid cell lines (LCLs) that had been identified using a
lymphocyte-specific gene array (17,856 cDNA Lymphochip mi-
croarray) (34). Approximately 9% (5 up, 1 down) overlapped with
the LMP1 transgenic lymphoma gene list, which is comparable to
the 4 to 5% overlap calculated from the LMP1-transfected GC B
cell comparison to LMP1 transgenic lymphocytes. This low degree
of overlap indicates that the effects of LMP1 expression in BL cells
and LCLs are different from those in the primary B-1a cells that
comprise the transgenic lymphomas.
DISCUSSION
These analyses of cellular expression reveal that LMP1 and
LMP2A can both alter host gene expression and that their coex-
pression is not necessarily additive but can induce distinct tran-
scriptional and functional effects. More than 1,000 genes were
identified with a 2-fold expression cutoff for all transgenic lym-
phocytes and lymphomas. The finding that 94% of these 2-fold
changes are changed in the same direction in every LMP1 lym-
phoma compared to the wild-type lymphoma affirms the con-
sistency of these changes (Fig. 2b). An independent method of
validation, qRT-PCR of genes from c-Kit and Stat3 pathways,
confirmed the direction and degree of change to levels that were
even more subtle than 2-fold (Table 2). By hierarchical clustering
and by comparing differential gene lists, cancer and inflammatory
response pathways were predicted to be affected in all transgenic
lymphocytes (LMP1, LMP2A, and LMP1/2A), with a potentially
unique effect on metabolic pathways for LMP1/2A lymphocytes
(Table 3). Importantly, expression findings from this study con-
firmed previous molecular identification of specific activation of
c-Rel and the requirement for Stat3-mediated signaling.
The comparison analyses with other EBV expression data sets
indicate that the effects of LMP1 and LMP2A can vary substan-
tially between mouse strains and cell lines. The very limited over-
lap between the LMP1 transgenic lymphocytes and the expression
studies of LMP1 in human cell lines is not surprising, considering
the very distinct cell types in which LMP1 was expressed. The
FIG 5 Cell viability analysis of transgenic splenic lymphocytes freshly har-
vested or from 1-day cultures with and without IL-4 supplementation.
(a) Freshly harvested splenic lymphocytes; (b and c) 1-day primary cultures of
splenocytes grown without (b) or with (c) IL-4 stimulation. Mean percentages
of live B cells (CD19, annexin V/propidium iodide negative) and the stan-
dard deviations are shown. Significant comparisons using the Student t test
(P  0.05) and the number of mice analyzed per group (n) are shown.
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transgenic lymphomas develop in B-1a lymphocytes, a cell type
prone to malignant conversion in mice, while the two studies in
human cells identified changes in GC, HL, and BL cells or LCLs,
each very distinct B cell types that likely impose constraints on the
effects of LMP1. However, the overall outcomes of expression
have similarities, with major effects on cell growth and prolifera-
tion, inflammatory response, cancer, and cell cycle. A similar
comparison of the effects of LMP2A in transgenic lymphocytes
with EBV-transformed LCLs and with HL cell lines identified
commonly affected pathways and biological functions; however,
the genes within each category were also unique to the cell type
(25).
The genes identified in each of these studies reveal multiple
ways through which LMP1 or LMP2A may affect cell function.
Potentially significant genes relevant to the promotion of cancer
identified for LMP1 lymphocytes included MYBL1, JAK2,
CHEK2, PDIA6, IL9R, and CD27 (Table 3). Additionally, genes
involved in B cell differentiation (CD27), cell cycle checkpoint
(CHEK2), and immune evasion (PDIA6) also likely contribute to
tumor progression. Overall, these changes in LMP1 lymphocytes
predict that LMP1 hyperactivates B cells, inducing cancer control
mechanisms such as the induction of cell cycle checkpoint and
potentially tumor-immune evasion mechanisms.
Many of the identified pathways for the LMP2A lymphocytes
have been previously shown to be affected by LMP2A in biological
studies. Activation of Notch signaling by LMP2A has been pre-
dicted to be linked to the downregulation
of transcription factors involved in B cell
development (25, 26). Additionally,
LMP2A has been shown to target the Wnt
pathway in lymphocytes and epithelial
cells through effects on Akt with nuclear
accumulation of -catenin (17, 23, 39),
while in this study expression of PTEN
was also decreased. Interestingly, the
c-Kit receptor signaling pathway, a recep-
tor tyrosine kinase and proto-oncogene
involved in a variety of hematological ma-
lignancies and solid cancers, most notably
chronic myeloid leukemia and gastroin-
testinal stromal tumor, was identified as a
significant pathway in LMP2A lympho-
cytes and LMP1 lymphomas.
Importantly, 70% of the changes de-
tected in LMP1/2A lymphocytes were also
affected by LMP1 or LMP2A expression
alone while the remaining one-third of
detected changes were unique to their
combined expression (Fig. 2a). Addition-
ally, the biological outcome of combined
expression resulted in a negation of both
phenotypes (Fig. 5b and c). The LMP1
transgenic lymphocytes had a slightly en-
hanced response to IL-4 while the LMP2A
lymphocytes had the highest viability
with or without IL-4. However, the dou-
bly transgenic lymphocytes did not re-
spond to IL-4 and had viability similar to
that of the negative lymphocytes. It has
recently been shown that in coexpressing
LMP1/2A transgenic B cells, LMP2A reversed the LMP1-mediated
block in GC formation although the reciprocal effects of LMP1 on
LMP2A function were not identified (37). These findings from
both studies indicate that the combined effects of coexpression
may not necessarily be additive and that coexpression can negate
their individual effects. Pathway overlap indicated that LMP1 and
LMP2A affect a differential set of lymphomagenesis-relevant
genes and that LMP1/2A coexpression modifies a subset of these
that were found to be commonly changed by LMP2A expression
alone (see Fig. S1 to S3 in the supplemental material). This type of
analysis highlights key cancer signaling candidates (e.g., c-Jun,
Myc, p15, and Bim) modulated by LMP1/2A coexpression and
reflects on the differential outcomes by coexpression.
The data presented here reveal very distinct effects on cell ex-
pression that will lead to the identification of additional pathways
that are distinctly regulated through the coexpression of LMP1
and LMP2A. These distinct and unique effects of LMP1 and
LMP2A expression also suggests that during EBV infection,
LMP1 and LMP2A expression is likely to be tightly regulated to
maximize their molecular properties. The identification of
genes uniquely affected by coexpression does suggest potential
synergistic effects. A combined effect of LMP1 and LMP2A has
recently been shown in LMP1/2A transgenic epithelial cells (40).
In this tumor initiation/promotion model of dimethylbenz--
anthracene (DMBA)/tetradecanoyl phorbol acetate (TPA)-
treated skin carcinogenesis, LMP1 functioned as a weak tumor
FIG 6 Comparison of differential gene lists from the current transgenic study with published data sets
grouped by functional categories. The percent overlap and the numbers of up-/downregulated genes are
indicated for each functional category. (a) LMP2A-regulated genes from transgenic splenic CD19 B
cells in the current study compared to the data set from the parental transgenic LMP2A mice (25); (b)
LMP1-regulated genes from transgenic splenic CD19 B cells in the current study compared to the
published data set on LMP1-regulated genes in transfected CD10 germinal center B cells (38). In
parentheses are the numbers of genes that are also regulated by Hodgkin lymphoma (HL) cell lines
relative to untransfected CD10 germinal center B cells as previously described (38).
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promoter to induce papilloma formation and coexpression with
LMP2A led to increased carcinoma progression. This was the first
evidence that coexpression of LMP1 and LMP2A can have an in-
creased oncogenic outcome.
In summary, findings in this study reveal that in different cell
types viral genes can alter critical cellular processes in multiple
ways through effects on different genes. These differences are ev-
ident between different mouse strains and even in the distinct
phenotypes of the LMP2A lineages that differ only in their levels of
LMP2A expression (6). It is likely that normal cellular expression
is very different between GC, BL, and HL cells and LCLs and the
B-1a transgenic lymphomas and that these differences contribute
to the distinct effects of the viral genes in these cell lines. This
interplay between cell and viral genes may also be a factor through
which EBV can be a contributing factor in very distinct types of
lymphoma and unique types of carcinomas.
MATERIALS AND METHODS
Ethics statement. Animals were housed at the University of North Caro-
lina at Chapel Hill in facilities accredited by the International Association
for the Assessment and Accreditation of Laboratory Animal Care. All
protocols were approved by the University of North Carolina Institutional
Animal Care and Use Committee (IACUC) (under IACUC protocol iden-
tifications 11-089, 09-247, 08-087, and 06-244), compliant with the
United States Public Health Service Policy on Humane Care and Use of
Laboratory Animals, the Amended Animal Welfare Act of 1985, and the
regulations of the United States Department of Agriculture (USDA) (An-
imal Welfare Assurance no. A3410-01; USDA registration no. 55-R-004).
This study was carried out in strict accordance with the recommendations
in the Guide for the Care and Use of Laboratory Animals of the National
Institutes of Health. To minimize suffering, animals were monitored daily
and euthanized when showing signs of abdominal distention.
Construction of transgenic mice. Transgenic LMP1 and LMP2A mice
driven by the immunoglobulin heavy chain promoter and enhancer have
been previously described (8, 19, 20). The lineages with the most clearly
defined phenotypes (lineage IL-3 for LMP1 showing 40% lymphoma in-
cidence versus 10% in control mice; lineage TgE for LMP2A showing
survival of immunoglobulin-negative cells and expressing the highest
level of transgene) were used for breeding (8, 20). LMP1 mice were kept
on a BALB/c background, and LMP2A mice were kept on a C57BL/6
background. Adult mice (6 months old) from the F1 generation of the
LMP1 and LMP2A breeding (negative littermates and LMP1, LMP2,
and LMP1/2/ mice) were used for microarray analysis of normal lym-
phocytes. Lymphoma cells from LMP1 transgenic and wild-type mice
were generated from a full BALB/c background and passaged in SCID
mice as previously described (20). Transgenic mice were maintained and
lymphoma passages were performed with the assistance of the Animal
Studies Core (University of North Carolina at Chapel Hill).
Splenic B cell isolation and analysis of transgene expression by
RT-PCR. Splenic lymphocytes and B cells were harvested and isolated as
previously described (20). Total RNA was prepared using the RNeasy
total RNA isolation kit (Qiagen) with DNase I treatment (Ambion). Ex-
pression of the transgenes was confirmed by RT-PCR as previously de-
scribed for LMP1 and using PCR primers LMP2-251R (5= GTGCTTACT
GCGGTTGTCACT 3=)/LMP2-690L (5= CACAGTTACAGCTCCAAGGA
3=) for LMP2A. RT-PCR for glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) was used as a positive control (40).
Cell survival analysis. Splenic lymphocytes were analyzed by flow
cytometry freshly after harvest and after 1 day in culture. Culture condi-
tions with and without IL-4 supplementation have been previously de-
scribed (20). Cell viability was assessed using annexin V-fluorescein iso-
thiocyanate (FITC) and propidium iodide (Invitrogen). The live B cell
population was identified as CD19 and annexin V/propidium iodide
negative. Statistical analysis of live cell enumerations was performed using
the Student t test (2 sided, unpaired) using the F test to calculate variance.
Preparation of RNA for microarray hybridization. DNase I-treated
total RNA was purified from freshly harvested CD19 splenic B cells.
Samples with a high RNA integrity index (RIN), 8, determined with an
Agilent 2100 Bioanalyzer, were used for microarray hybridization. For
comparative analysis, the same RNA pooled from multiple wild-type
BALB/c mice was used as the reference sample for all hybridizations. For
lymphocyte analysis, RNA was pooled from multiple mice to normalize
for anomaly effects and hybridized in duplicate to two Agilent 4-by-44K
microarray chips. For lymphoma cell analysis, 3 LMP1 lymphomas (high/
medium/low expression) and 1 wild-type lymphoma were separately hy-
bridized to one 4-by-44K microarray chip. The biological properties of
these lymphomas have been previously described and refer to lymphoma
numbers 2 (high), 6 (medium), and 5 (low) for LMP1 and lymphoma
number 1 for the wild-type lymphoma (20).
qRT-PCR. Complementary DNA was synthesized from 50 ng total
RNA (Transcriptor; Roche). PCRs were run in triplicate for 2 biological
replicates and a negative control without reverse transcriptase (RT). To
calculate relative change, the second derivative maximum method was
applied. This allows for more precise quantitation by being independent
of baseline estimations.
Bioinformatics analysis. GeneSpring GX software (Agilent) was used
to process microarray raw data and used for analyses by hierarchical clus-
tering, GO term enrichment, Venn diagrams, and significant pathway
analysis. IPA software was used for predicting c-Rel and Stat3 transcrip-
tional targets, for calculating enrichment of differential gene lists to IPA
curated biological functions and canonical signaling pathways, and for
comparative analysis with specific published data sets. Differential gene
lists were generated by applying a 2-fold-change cutoff on normalized
data filtered on expression values and flags. The Core Analysis function in
IPA was used to calculate enrichment of differential gene lists using Fish-
er’s exact test (P  0.05). To refine the database search, limits were set in
Core Analysis to consider only information that has been experimentally
observed and in tissues/cell lines relevant to the spleen or of lymphocyte
origin. Normalized expression values of Stat3 and c-Rel transcriptional
targets were displayed as scatter plots in GeneSpring GX, and the Pearson
correlation coefficient r was calculated in Excel using the CORREL func-
tion.
Microarray data accession number. Microarray data are deposited in
Gene Expression Omnibus, accession number GSE38954.
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